Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
Authors:
- Bao Nguyen ToanBTBao Nguyen Toan
- Nguyen Nguyen HuyenNHNguyen Nguyen Huyen
- Pierce Kah-Hoe ChowPCPierce Kah-Hoe Chow
Top Cited Papers
Open Access
- 1 April 2023
- journal article
- review article
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 29 (2) , 277-292
Abstract
Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP has its challenges, including accuracy dependent on its cut-off levels, degree of liver necroinflammation, and etiology of liver disease. Though various studies have demonstrated the utility of protein induced by vitamin K absence II (PIVKA-II) in surveillance, treatment monitoring, and predicting recurrence, it is still not recommended as a routine biomarker test. A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and treatment monitoring of HCC, based on six predetermined statements. The experts agreed that PIVKA-II was valuable in the detection of HCC in AFP-negative patients, and could potentially benefit detection of early HCC in combination with AFP. PIVKA-II is clinically useful for monitoring curative and intra-arterial locoregional treatments, outcomes, and recurrence, and could potentially predict microvascular invasion risk and facilitate patient selection for liver transplant. However, combining PIVKA-II with US and AFP for HCC surveillance, including small HCC, still requires more evidence, whilst its role in detecting AFP-negative HCC will potentially increase as more patients are treated for hepatitis-related HCC. PIVKA-II in combination with AFP and US has a clinical role in the Asia-Pacific region for surveillance. However, implementation of PIVKA-II in the region will have some challenges, such as requiring standardization of cut-off values, its cost-effectiveness and improving awareness among healthcare providers.Keywords
Funding Information
- Abbott
- BMS
- Gilead
- Merck
- AMiLi
- MiRXES
- Perspectum
- Roche
- Janssen
- MSD
- Vir Biotech
This publication has 62 references indexed in Scilit:
- Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolizationInternational Journal of Clinical Oncology, 2013
- Clinical Utility of Des-γ-Carboxy Prothrombin Kinetics as a Complement to Radiologic Response in Patients with Hepatocellular Carcinoma Undergoing Transarterial ChemoembolizationJournal of Vascular and Interventional Radiology, 2012
- Combined measurement of preoperative α‐fetoprotein and des‐γ‐carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis‐B‐related hepatocellular carcinomaInternational Journal of Cancer, 2012
- Des-γ-Carboxy Prothrombin and α-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular CarcinomaGastroenterology, 2010
- α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular CarcinomaGastroenterology, 2009
- Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose PeginterferonNew England Journal of Medicine, 2008
- Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic reviewHepatology International, 2007
- PIVKA-II Is a Useful Tumor Marker for Recurrent Hepatocellular Carcinoma after Surgical ResectionOncology, 2007
- Extending indicationLiver Transplantation, 2007
- Des-γ-carboxy (abnormal) prothrombin and hepatocellular carcinoma: A critical reviewHepatology, 1993